A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine

Real World Evidence of Population Differences in Allopurinol‐Related Severe Cutaneous Adverse Reactions in East Asians: A Population‐Based Cohort Study

(2021) Tsugumichi Sato et al.   CTS-Clinical and Translational Science

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines

(2021) Heshu Abdullah-Koolmees et al.   Frontiers in Pharmacology

Pharmacogenomics research and its clinical implementation in Thailand: Lessons learned from the resource-limited settings

(2021) Chonlaphat Sukasem et al.   Drug Metabolism and Pharmacokinetics

HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients

(2021) Patompong Satapornpong et al.   Frontiers in Immunology

HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease

(2021) Christina Sze-Man Wong et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis

(2021) Chonlaphat Sukasem et al.   PHARMACOGENOMICS JOURNAL

Genetics of Severe Cutaneous Adverse Reactions

(2021) Shang-Chen Yang et al.   Frontiers in Medicine

Genetic and clinical risk factors associated with phenytoin‐induced cutaneous adverse drug reactions in Thai population

(2020) Chonlaphat Sukasem et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Association of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients

(2020) Francis Capule et al.   PHARMACOGENOMICS JOURNAL

Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics

(2020) Patompong Satapornpong et al.   Frontiers in Pharmacology

Genetic association of co‐trimoxazole‐induced severe cutaneous adverse reactions is phenotype‐specific: HLA class I genotypes and haplotypes

(2020) Chonlaphat Sukasem et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature

(2020) Grace Y. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

2020 American College of Rheumatology Guideline for the Management of Gout

(2020) John D. FitzGerald et al.   ARTHRITIS CARE & RESEARCH

Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost‐Effectiveness of Preemptive Pharmacogenetic Testing

(2020) Yitian Zhou et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses

(2020) Hye Jung Park et al.   Expert Opinion On Drug Safety

Whole Genome Sequencing Identifies Genetic Variants Associated with Co-trimoxazole Hypersensitivity in Asians

(2020) Chuang-Wei Wang et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice

(2020) Mariamena Arbitrio et al.   CTS-Clinical and Translational Science

Clinical Presentation and Management of Atypical and Recalcitrant Acute Generalized Exanthematous Pustulosis (AGEP)

(2020) Mohammad Amin Hadavand et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia

(2020) Hana Krismawati et al.   PLoS Neglected Tropical Diseases

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study

(2019) Karam Mounzer et al.   AIDS Research and Therapy

Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy

(2019) Hong Liu et al.   JAMA Dermatology

Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review

(2019) Shan Zhang et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019

(2019) Tetsuo Shiohara et al.   ALLERGOLOGY INTERNATIONAL

Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting

(2019) Thomas Fowler et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

IPD-IMGT/HLA Database

(2019) James Robinson et al.   NUCLEIC ACIDS RESEARCH

A stepwise approach to implementing pharmacogenetic testing in the primary care setting

(2019) Kristin Wiisanen Weitzel et al.   PHARMACOGENOMICS

Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study

(2018) Sarah F Keller et al.   ANNALS OF THE RHEUMATIC DISEASES

Education and Knowledge in Pharmacogenomics: Still a Challenge?

(2018) Jyothsna Giri et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

(2018) Elizabeth J. Phillips et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions

(2018) Wimonchat Tangamornsuksan et al.   JAMA Dermatology

Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population

(2018) Taisei Mushiroda et al.   JAMA Neurology

Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients

(2018) Chonlaphat Sukasem et al.   Journal of Immunology Research

Genetic markers of severe cutaneous adverse reactions

(2018) Jae-Woo Jung et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Current landscape of personalized medicine adoption and implementation in Southeast Asia

(2018) Huey Yi Chong et al.   BMC Medical Genomics

Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis

(2018) Barbara Meier-Schiesser et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA ‐B*5701 Screening as a Risk‐Mitigation Measure

(2018) Chris M. Stainsby et al.   PHARMACOTHERAPY

HLA testing in the molecular diagnostic laboratory

(2018) Kathleen Madden et al.   VIRCHOWS ARCHIV

Efficacy of the HLA-B∗58:01 Screening Test in Preventing Allopurinol-Induced Severe Cutaneous Adverse Reactions in Patients with Chronic Renal Insufficiency—A Prospective Study

(2018) Heung-Woo Park et al.   Journal of Allergy and Clinical Immunology-In Practice

The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions

(2017) Patricia T. Illing et al.   IMMUNOGENETICS

The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK

(2017) Noel Frey et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis

(2017) Jennifer Sorrell et al.   PEDIATRIC DERMATOLOGY

Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population

(2017) Niwat Saksit et al.   Pharmacogenetics and Genomics

Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13

(2017) Therdpong Tempark et al.   Pharmacogenetics and Genomics

Association of the HLA-B alleles with carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype

(2017) Rika Yuliwulandari et al.   PHARMACOGENOMICS

Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx)

(2017) Nicolas Picard et al.   THERAPIE

Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles

(2017) James Robinson et al.   PLoS Genetics

Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

(2017) Stefanie Zimmermann et al.   JAMA Dermatology

Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population

(2017) Napatrupron Koomdee et al.   Frontiers in Pharmacology

HLA Association with Drug-Induced Adverse Reactions

(2017) Wen-Lang Fan et al.   Journal of Immunology Research

Characterization of Children With Recurrent Episodes of Stevens Johnson Syndrome

(2017) Daniel Olson et al.   Journal of the Pediatric Infectious Diseases Society

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis

(2017) Kanoot Jaruthamsophon et al.   Scientific Reports

Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association

(2016) Seema Mital et al.   Circulation-Cardiovascular Genetics

Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges

(2016) MJ Arwood et al.   CTS-Clinical and Translational Science

Multidisciplinary model to implement pharmacogenomics at the point of care

(2016) Pedro J. Caraballo et al.   GENETICS IN MEDICINE

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

(2016) Kelly E. Caudle et al.   GENETICS IN MEDICINE

The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions

(2016) Nasreen Hassoun-Kheir et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Severe cutaneous adverse drug reactions

(2016) Wen-Hung Chung et al.   JOURNAL OF DERMATOLOGY

Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults

(2016) Derek Y. Hsu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

(2016) James M Hoffman et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics

(2016) A. Pinho et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians

(2016) Chun-Bing Chen et al.   NEUROLOGY

Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population

(2016) Wichittra Tassaneeyakul et al.   Pharmacogenetics and Genomics

A success story in pharmacogenomics: genetic ID card for SJS/TEN

(2016) Chonlaphat Sukasem et al.   PHARMACOGENOMICS

Racial disparities in the risk of Stevens–Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States

(2016) Na Lu et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association

(2016) Seema Mital et al.   Circulation-Cardiovascular Genetics

HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand

(2016) Chonlaphat Sukasem et al.   Frontiers in Pharmacology

Determining performance characteristics of an NGS-based HLA typing method for clinical applications

(2016) J. L. Duke et al.   HLA

Drug reaction with eosinophilia and systemic symptoms syndrome

(2015) Sarah Spriet et al.   ALLERGY AND ASTHMA PROCEEDINGS

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update

(2015) Roni P. Dodiuk-Gad et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Drug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics

(2015) Chonlaphat Sukasem et al.   Annual Review of Genomics and Human Genetics

An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing

(2015) Jae-Woo Jung et al.   GENETICS IN MEDICINE

Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01

(2015) Bernardo Sousa-Pinto et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis

(2015) Peng Zhou et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Acute generalized exanthematous pustulosis (AGEP): A review and update

(2015) Jesse Szatkowski et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Allopurinol hypersensitivity: investigating the cause and minimizing the risk

(2015) Lisa K. Stamp et al.   Nature Reviews Rheumatology

Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions

(2015) Thachanan Kongpan et al.   Pharmacogenetics and Genomics

Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea

(2015) Dong-Jin Park et al.   ARTHRITIS CARE & RESEARCH

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study

(2015) Tai-Ming Ko et al.   BMJ-British Medical Journal

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study

(2015) Tai-Ming Ko et al.   BMJ-British Medical Journal

HLA Typing for the Next Generation

(2015) Neema P. Mayor et al.   PLoS One

Safety and Efficacy of Allopurinol in Chronic Kidney Disease

(2014) Maria Miller Thurston et al.   ANNALS OF PHARMACOTHERAPY

Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis

(2014) M. Kakeda et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Prerequisites to Implementing a Pharmacogenomics Program in a Large Health-Care System

(2014) K D Levy et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update

(2014) M A Martin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review

(2014) V. L. M. Yip et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions

(2014) Ursula Amstutz et al.   EPILEPSIA

Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China

(2014) Dan Sun et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Implementation of personalized medicine services in community pharmacies: Perceptions of independent community pharmacists

(2014) Katelyn M. Alexander et al.   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions

(2014) Z. Chen et al.   NEUROLOGY

Abacavir Induced T Cell Reactivity from Drug Naïve Individuals Shares Features of Allo-Immune Responses

(2014) Jacqueline Adam et al.   PLoS One

Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population

(2014) Surasak Saokaew et al.   PLoS One

Stevens-John syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management

(2014) Maja Mockenhaupt   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

HLA typing by next-generation sequencing - getting closer to reality

(2014) C. Gabriel et al.   TISSUE ANTIGENS

A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children

(2013) C. Ferrandiz-Pulido et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome

(2013) Suran L Fernando   AUSTRALASIAN JOURNAL OF DERMATOLOGY

HLA-B*58:01is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population

(2013) M. Gonçalo et al.   BRITISH JOURNAL OF DERMATOLOGY

In vitrodrug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test

(2013) G. Porebski et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand

(2013) Waranya Rattanavipapong et al.   EPILEPSIA

Population-specific recombination sites within the human MHC region

(2013) T H Lam et al.   HEREDITY

Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury

(2013) Nahoko Kaniwa et al.   JOURNAL OF HUMAN GENETICS

Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis

(2013) Alexander A. Navarini et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

DRESS syndrome

(2013) Zain Husain et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Toxic epidermal necrolysis

(2013) Robert A. Schwartz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Toxic epidermal necrolysis

(2013) Robert A. Schwartz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Community pharmacists‘ attitudes towards clinical utility and ethical implications of pharmacogenetic testing

(2013) Sony Tuteja et al.   Personalized Medicine

HLA alleles and hypersensitivity to carbamazepine

(2013) Sandeep Grover et al.   Pharmacogenetics and Genomics

Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists

(2013) Rachel Mills et al.   PHARMACOGENOMICS

HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis

(2013) E Genin et al.   PHARMACOGENOMICS JOURNAL

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine

(2013) YongLi Guo et al.   Science China-Life Sciences

Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand

(2013) Somsak Tiamkao et al.   International Journal of Clinical Pharmacy

Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

(2013) Wimonchat Tangamornsuksan et al.   JAMA Dermatology

Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA

(2012) J. Yun et al.   ALLERGY

The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis

(2012) Y.-C. Huang et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing

(2012) M S Hershfield et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing

(2012) M A Martin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods

(2012) Laura Stocchi et al.   CURRENT GENOMICS

Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis

(2012) Wen-Hung Chung et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Making pharmacogenetic testing a reality in a community pharmacy

(2012) Shanna K. O’Connor et al.   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

(2012) D. Dong et al.   NEUROLOGY

Prevalence of HLA-B*5701 among HIV-Infected Children in Thailand and Cambodia

(2012) Thanyawee Puthanakit et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

HLA DNA typing: past, present, and future

(2012) H. Erlich   TISSUE ANTIGENS

The DRESS Syndrome: A Literature Review

(2011) Patrice Cacoub et al.   AMERICAN JOURNAL OF MEDICINE

Assessment of the Pharmacogenomics Educational Needs of Pharmacists

(2011) Kristen B. McCullough et al.   AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION

Drug Hypersensitivity and Human Leukocyte Antigens of the Major Histocompatibility Complex

(2011) Mandvi Bharadwaj et al.   Annual Review of Pharmacology and Toxicology

Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis

(2011) Y. H. Tang et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans

(2011) Sae-Hoon Kim et al.   EPILEPSY RESEARCH

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

(2011) M. H. Lee et al.   INTERNAL MEDICINE JOURNAL

Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population

(2011) Choong-Chor Chang et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis

(2011) A. F. Cristallo et al.   International Journal of Immunogenetics

Pharmacogenomics in a community pharmacy: ACT now

(2011) Lisa Padgett et al.   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency

(2011) J.-W. Jung et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans

(2011) Hye-Ryun Kang et al.   Pharmacogenetics and Genomics

Statistical Analysis of Stevens-Johnson Syndrome Caused by Mycoplasma pneumonia Infection in Japan

(2011) Yuko Kunimi et al.   ALLERGOLOGY INTERNATIONAL

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

(2010) B Sassolas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

(2010) Nahoko Kaniwa et al.   EPILEPSIA

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

(2010) Wichittra Tassaneeyakul et al.   EPILEPSIA

The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques

(2010) W. M. Howell et al.   JOURNAL OF CLINICAL PATHOLOGY

Nomenclature for factors of the HLA system, 2010

(2010) S. G. E. Marsh et al.   TISSUE ANTIGENS

HLA, immunogenetics, pharmacogenetics and personalized medicine

(2010) D. Charron   VOX SANGUINIS

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

(2009) Benjamin Young et al.   AIDS

Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America

(2009) Judith A. Aberg et al.   CLINICAL INFECTIOUS DISEASES

Acute generalized exanthematous pustulosis

(2009) Sima Halevy   Current Opinion in Allergy and Clinical Immunology

Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis

(2009) N. Levi et al.   PEDIATRICS

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

(2009) Wichittra Tassaneeyakul et al.   Pharmacogenetics and Genomics

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

(2008) Michael Saag et al.   CLINICAL INFECTIOUS DISEASES

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population

(2008) Chaichon Locharernkul et al.   EPILEPSIA

Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis

(2008) Chizuko Koga et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis

(2008) Wen-Hung Chung et al.   NATURE MEDICINE

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

A European study of HLA-B in Stevens???Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

(2008) Christine Lonjou et al.   Pharmacogenetics and Genomics

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis

(2008) Nahoko Kaniwa et al.   PHARMACOGENOMICS

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility

(2008) A R Hughes et al.   PHARMACOGENOMICS JOURNAL

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

(2007) Sima Halevy et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY